|
| Thursday, June 2, 2022 |
|
|
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares |
| On June 1, 2022, TOT BIOPHARM (Stock code: 1875. HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and Centerlab agreed to subscribe for 116,250,000 and 33,750,000 shares of TOT BIOPHARM more info >> |
|
| Wednesday, June 1, 2022 |
|
|
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares |
| TOT BIOPHARM (Stock code: 1875. HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and Centerlab agreed to subscribe for 116,250,000 and 33,750,000 shares of TOT BIOPHARM more info >> |
|
| Friday, August 13, 2021 |
|
|
TOT BIOPHARM 2021 Interim Revenue Surges 78% to RMB23.13 million |
| TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Group"; stock code: 1875.HK), a biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its unaudited interim results for the six months ended 30 June 2021. more info >> |
|
| Wednesday, March 24, 2021 |
|
|
TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020 |
| TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its audited annual results for the year ended 31 December 2020. more info >> |
|
| Friday, October 16, 2020 |
|
|
TOT BIOPHARM International Company Limited Optimises Company Management Structure to Promote Strategic Development Upgrade |
| TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), is pleased to announce that Ms. Yeh-Huang, Chun-Ying, Executive Director, has been appointed as Vice Chairman of the Board while she has resigned as General Manager of the Company. more info >> |
|
| Wednesday, April 22, 2020 |
|
|
TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical Trial |
| TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK) is pleased to announce that the randomized Phase III clinical trial of TAB008 (Pusintin) has recently reached the predefined primary endpoint. more info >> |
|
| Wednesday, March 18, 2020 |
|
|
TOT BIOPHARM Announces 2019 Annual Results |
| TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its audited annual results for the year ended 31 December 2019. more info >> |
|
| Monday, March 9, 2020 |
|
|
TOT BIOPHARM Garners "Listing Award of Technological Company" and "Innovative Technological Research and Development Award" |
| On 6 March 2020, a morale-enhancing conference themed "Working Towards a World-class High-tech ePark & a New Summit for Reform and Opening-up in the New Era" was held at Suzhou Industrial Park more info >> |
|
| Thursday, January 2, 2020 |
|
|
TOT BIOPHARM Biological Drug R&D Project Makes List of National Major Scientific and Technological Special Projects for "Significant New Drug Development" |
| TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK) is pleased to announce that the Company has received notice of Project Topics of 2019 Implementation Plan of Major Special Technology Projects for "Significant New Drug Creation" more info >> |
|
| Monday, December 16, 2019 |
|
|
TOT BIOPHARM Included in the "Suzhou Industrial Park - 2019 Awarded Listed Enterprises" |
| TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company"; stock code: 1875.HK) is pleased to announce that the Company, a high-tech enterprise located in the Suzhou Industrial Park, was successfully listed on the Main Board of the Stock Exchange of Hong Kong on 8 November this year. more info >> |
|
|
|
